WEBULL
News
LXRX
1.200
-2.44%
-0.030
Weekly Report: what happened at LXRX last week (0202-0206)?
Weekly Report · 1d ago
LEXICON ANNOUNCES CLOSING OF APPROXIMATELY $94.6 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT
Reuters · 3d ago
Major Insider Makes Bold New Bet on Biotech Player
TipRanks · 5d ago
Lexicon Pharmaceuticals Bolsters Capital Through Equity Financing
TipRanks · 02/02 22:17
Weekly Report: what happened at LXRX last week (0126-0130)?
Weekly Report · 02/02 09:36
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer
Reuters · 01/30 18:38
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 01/30 17:05
Gold Tumbles Over 6%; Apple Posts Upbeat Earnings
Benzinga · 01/30 17:05
Midday Fly By: Warsh nominated for Fed chair, Apple reports Q1 beat
TipRanks · 01/30 17:01
BUZZ-U.S. STOCKS ON THE MOVE-Charter Communications, Western Digital, Regeneron
Reuters · 01/30 15:42
Lexicon Pharma Shares Drop After Public Offering Prices
Dow Jones · 01/30 15:12
BUZZ-Lexicon Pharma tumbles on equity offering, private placement with top shareholder
Reuters · 01/30 13:45
Lexicon 32M share Spot Secondary priced at $1.30
TipRanks · 01/30 11:05
Lexicon Prices $94.6 Mln Public Offering And Concurrent Private Placement; Stock Down
NASDAQ · 01/30 11:01
Lexicon Pharmaceuticals prices $94.6M share offering
Seeking Alpha · 01/30 08:33
*Lexicon to Use Net Proceeds to Fund R&D of Drug Candidates, Among Other Purposes >LXRX
Dow Jones · 01/30 08:14
*Lexicon: Expect Additional Gross Proceeds of About $11.9M >LXRX
Dow Jones · 01/30 08:13
*Lexicon Private Placement Purchaser Also Agrees to Buy Additional 182,779 Shrs of Series B Convertible Preferred Stock >LXRX
Dow Jones · 01/30 08:12
*Lexicon Also Announces $41.1M Concurrent Private Placement >LXRX
Dow Jones · 01/30 08:06
*Lexicon Pharmaceuticals Underwriters Have Option to Buy Additional 4.8M Shares >LXRX
Dow Jones · 01/30 08:00
More
Webull provides a variety of real-time LXRX stock news. You can receive the latest news about Lexicon Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.